TANG CAPITAL MANAGEMENT LLC
Q1 2024 Form 13-F
SAN DIEGO, CALIFORNIA
CIK 0001232621
· Institutional investment manager
Consolidated report · includes
1 manager
since Q2 2013
$960.4M Reported Value Total
Reported value
$960.4M
Quarter over quarter
+17.2%
Holdings
99
Top-10 concentration
38.4%
Filing Structure
Reports holdings for
- TANG KEVIN C · File #028-14818 · since Q2 2013
Key People
Named on the latest Form 13-F filing — not necessarily an owner
Kevin Tang
Manager
Filing Navigation
Coverage begins with the second quarter of 2013. Earlier quarters are not shown while their accuracy is being verified.
13F Metrics
Loading 13F Metrics
Q1 2024 13F record
Q1 2024 13F filing summary
| Period of report | March 31, 2024 |
|---|---|
| Filed | May 15, 2024 |
| Form | 13F-HR |
| Reported value | $960.4M |
| Positions | 99 |
| Change in reported value | -11.3% |
| New positions | 25 |
| Exited positions | 49 |
| Position turnover | 50.0% |
| Top-10 concentration | 38.4% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
40 | $2.2B |
|
Q1 2026 13F
Filed May 15, 2026
|
51 | $2.0B |
|
Q4 2025 13F
Filed Feb 17, 2026
|
75 | $2.0B |
|
Q3 2025 13F
Filed Nov 14, 2025
|
194 | $2.6B |
|
Q2 2025 13F
Filed Aug 14, 2025
|
200 | $2.0B |
|
Q1 2025 13F
Filed May 15, 2025
|
202 | $1.8B |
|
Q4 2024 13F
Filed Feb 14, 2025
|
183 | $1.5B |
|
Q3 2024 13F
Filed Nov 14, 2024
|
154 | $1.4B |
|
Q2 2024 13F
Filed Aug 14, 2024
|
127 | $981.9M |
|
Q1 2024 13F
Filed May 15, 2024
|
99 | $960.4M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
123 | $1.1B |
|
Q3 2023 13F
Filed Nov 14, 2023
|
106 | $708.7M |
|
Q2 2023 13F
Filed Aug 14, 2023
|
99 | $679.3M |
|
Q1 2023 13F
Filed May 15, 2023
|
103 | $671.1M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
89 | $688.3M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
95 | $815.4M |
|
Q2 2022 13F
Filed Aug 15, 2022
|
67 | $659.0M |
|
Q1 2022 13F
Filed May 16, 2022
|
51 | $499.9M |
|
Q4 2021 13F
Filed Feb 14, 2022
|
29 | $497.2M |
|
Q3 2021 13F
Filed Nov 15, 2021
|
20 | $481.7M |
33 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q1 2024
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | TARS TARSUS PHARMACEUTICALS INC | $82.0M | 8.53% |
| 2 | EOLS EVOLUS INC | $58.1M | 6.05% |
| 3 | KALV KALVISTA PHARMACEUTICALS INC | $48.9M | 5.09% |
| 4 | ANAB ANAPTYSBIO INC | $30.0M | 3.12% |
| 5 | MIRM MIRUM PHARMACEUTICALS INC | $29.8M | 3.1% |
| 6 | ALT ALTIMMUNE INC | $28.0M | 2.91% |
| 7 | IMCR IMMUNOCORE HLDGS PLC | $26.4M | 2.74% |
| 8 | INBX INHIBRX INC | $24.5M | 2.55% |
| 9 | LLY ELI LILLY & CO | $21.0M | 2.19% |
| 10 | PCVX VAXCYTE INC | $20.5M | 2.13% |
| 11 | PTCT PTC THERAPEUTICS INC | $20.4M | 2.12% |
| 12 | OTLK OUTLOOK THERAPEUTICS INC | $19.3M | 2.01% |
| 13 | RCKT ROCKET PHARMACEUTICALS INC | $17.8M | 1.85% |
| 14 | IMNM IMMUNOME INC | $17.8M | 1.85% |
| 15 | AVDL AVADEL PHARMACEUTICALS PLC | $17.7M | 1.84% |
| 16 | VTYX VENTYX BIOSCIENCES INC | $17.1M | 1.78% |
| 17 | AVIR ATEA PHARMACEUTICALS INC | $16.5M | 1.71% |
| 18 | ELEV ELEVATION ONCOLOGY INC | $15.7M | 1.63% |
| 19 | APLT APPLIED THERAPEUTICS INC | $15.2M | 1.58% |
| 20 | ACET ADICET BIO INC | $15.1M | 1.57% |
Values as reported on the Q1 2024 Form 13F. Every position is in the holdings table below.